Skip to main content


Question for Department of Health and Social Care

UIN 12336, tabled on 8 June 2021

To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the potential merits of the Alzheimer’s drug Aduhelm.

Answered on

2 July 2021

The Medicines and Healthcare products Regulatory Agency (MHRA) is monitoring regulatory developments regarding Aducanumab (Aduhelm). We are unable to formally comment on any product that is not approved for use in the United Kingdom due to commercial and market sensitivities surrounding the approval process of a product. As with all other treatments for life threatening or debilitating conditions, the MHRA will ensure a thorough and expedited assessment of this medicine.